CTMX
CTMX
US23284F1057
CytomX Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 76.201.000 138.103.000
44.8%
Cost of Revenue -- --
--
Gross Profit -- --
--
98.565.000 113.108.000
12.9%
Operating Income -22.364.000 24.995.000
189.5%
Pretax Income -17.130.000 32.093.000
153.4%
Net Income Common Stockholders -17.368.000 31.869.000
154.5%
-- --
--
-- --
--
ende